Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed attachment file name title grouped question UIN question first answered answering member label
tabling member	label

Search

1025353

registered interest
date	14/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what action they are taking to negotiate a reduction of the cost of liothyronine (T3) for use in primary care.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12319
answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>Liothyronine is an unbranded generic medicine. The Department encourages competition between suppliers of unbranded generic medicines to keep prices down. This generally works well and has led to some of the lowest prices in Europe.</p><p>Concerns about anti-competitive behaviour are a matter for the Competition and Markets Authority (CMA) to investigate. Liothyronine, marketed by Concordia, is currently the subject of an investigation by the CMA, which has provisionally found that Concordia abused its dominant position to overcharge the National Health Service by millions for liothyronine tablets. A provisional decision does not necessarily lead to an infringement decision. Where companies have breached competition law, the Department will seek damages and invest that money back into the NHS.</p><p>The Department also has its own powers to limit prices of unbranded generic medicines and will consult early in 2019 with the relevant industry bodies on implementation of those powers.</p> answering member printed Lord O'Shaughnessy question first answered 20/12/2018 15:44:26 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1020276

registered interest
date	05/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospitals: Wheelchairs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the availability of sufficient wheelchairs in NHS hospitals for disabled people visiting patients.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12068
answer	answer is ministerial correction date of answer 19/12/2018 answer text <p>No central guidance is provided by the Department and no such assessments have been made.</p><p> </p><p>All National Health Service trusts as public organisations are subject to the general duty in the Equality Act 2010 to have due regard to the need to take steps to meet the needs of persons who share a relevant protected characteristic that are different from the needs of persons who do not share it. Disability is a protected characteristic.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL12069 HL12070 HL12071 question first answered 19/12/2018 12:46:53 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1020277

registered interest
date	05/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospitals: Wheelchairs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what guidance is provided to NHS Hospital Trusts about the provision of wheelchairs for disabled people visiting patients.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12069
answer	answer is ministerial correction date of answer 19/12/2018 answer text <p>No central guidance is provided by the Department and no such assessments have been made.</p><p> </p><p>All National Health Service trusts as public organisations are subject to the general duty in the Equality Act 2010 to have due regard to the need to take steps to meet the needs of persons who share a relevant protected characteristic that are different from the needs of persons who do not share it. Disability is a protected characteristic.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL12068 HL12070 HL12071 question first answered 19/12/2018 12:46:53 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1020279

registered interest
date	05/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospitals: Wheelchairs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of whether the information provided to disabled people visiting NHS patients about the availability of wheelchairs in NHS hospitals is adequate.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12070
answer	answer is ministerial correction date of answer 19/12/2018 answer text <p>No central guidance is provided by the Department and no such assessments have been made.</p><p> </p><p>All National Health Service trusts as public organisations are subject to the general duty in the Equality Act 2010 to have due regard to the need to take steps to meet the needs of persons who share a relevant protected characteristic that are different from the needs of persons who do not share it. Disability is a protected characteristic.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL12068 HL12069 HL12071 question first answered 19/12/2018 12:46:53 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1020280

registered interest
date	05/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospitals: Wheelchairs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what guidance they provide to NHS hospital trusts about policies concerning the availability of wheelchairs for disabled visitors, in particular on the review and publication of those policies.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12071
answer	answer is ministerial correction date of answer 19/12/2018 answer text <p>No central guidance is provided by the Department and no such assessments have been made.</p><p> </p><p>All National Health Service trusts as public organisations are subject to the general duty in the Equality Act 2010 to have due regard to the need to take steps to meet the needs of persons who share a relevant protected characteristic that are different from the needs of persons who do not share it. Disability is a protected characteristic.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL12068 HL12069 HL12070 question first answered 19/12/2018 12:46:53 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1010121

registered interest
date	19/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Records: Databases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many people used the national data opt-out online service from NHS Digital to (1) opt out, and (2) to opt back in having previously opted out, in October 2018.
tabling member printed	Lord Hunt of Kings Heath
uin	HL11568
answer	answer is ministerial correction date of answer 29/11/2018 answer text <p>The online national data opt-out service was visited by 7,106 people during October 2018. Of these 453 set a new opt-out, and 113 chose to reverse an existing opt-out.</p> answering member printed Lord O'Shaughnessy question first answered 29/11/2018 17:08:05 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

980146

registered interest
date	01/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Royal Free London NHS Foundation Trust: DeepMind
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what estimate they have made of the cost to the public of inquiries by the Information Commissioner's Office (ICO), National Data Guardian, Medicines and Healthcare products Regulatory Agency, and NHS Digital, resulting from the agreement for the Royal Free Hospital to provide data to DeepMind which the ICO found to be unlawful.
tabling member printed	Lord Hunt of Kings Heath
uin	HL10415
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>The Department has made no such estimate.</p> answering member printed Lord O'Shaughnessy question first answered 15/10/2018 13:57:03 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

980147

registered interest
date	01/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how the proposed statutory scheme for branded drugs will improve access to cost-effective medicines for patients in the UK.
tabling member printed	Lord Hunt of Kings Heath
uin	HL10416
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>The proposals outlined in the recent consultation, <em>Proposed changes to the statutory scheme to control the costs of branded health service medicines</em>, ensure that the scheme can continue to fulfil its purpose of safeguarding the financial position of the National Health Service, alongside the voluntary Pharmaceutical Price Regulation Scheme. A copy of the consultation document is attached. The proposals set out in the recent consultation are aimed at constraining the cost of branded health service medicines to a level that balances the interests of patients, the NHS, industry and the taxpayer. The consultation’s impact assessment demonstrates significant overall benefits to patient health, driven by the reinvestment of any savings generated from the statutory scheme in NHS budgets. A copy of the impact assessment, <em>2018 Statutory Scheme for Branded Medicines Pricing</em>, is attached.</p><p>There is a wider framework in place to ensure the cost-effectiveness of medicines used in the NHS, most importantly, through National Institute for Health and Care Excellence (NICE) appraisals. This existing framework remains unchanged by the proposals set out in the consultation, with the NHS still required to fund all medicines approved through a NICE technology appraisal. The Department is committed to ensuring access to clinically and cost-effective medicines, and is working with NHS England and the pharmaceutical industry to support improvements in the speed and rate of access to new medicines for NHS patients.</p><p> </p> answering member printed Lord O'Shaughnessy attachment 1 file name Statutory_Scheme_Consultation_Document_corrected.pdf title Proposed changes to the statutory scheme 2 file name 2018_Statutory_Scheme_Impact_Assessment_1.pdf title Statutory Scheme Impact Assessment grouped question UIN HL10417 question first answered 15/10/2018 10:59:00 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

980148

registered interest
date	01/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether the proposals outlined in the draft branded drugs statutory scheme will improve access to innovative medicines in the UK.
tabling member printed	Lord Hunt of Kings Heath
uin	HL10417
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>The proposals outlined in the recent consultation, <em>Proposed changes to the statutory scheme to control the costs of branded health service medicines</em>, ensure that the scheme can continue to fulfil its purpose of safeguarding the financial position of the National Health Service, alongside the voluntary Pharmaceutical Price Regulation Scheme. A copy of the consultation document is attached. The proposals set out in the recent consultation are aimed at constraining the cost of branded health service medicines to a level that balances the interests of patients, the NHS, industry and the taxpayer. The consultation’s impact assessment demonstrates significant overall benefits to patient health, driven by the reinvestment of any savings generated from the statutory scheme in NHS budgets. A copy of the impact assessment, <em>2018 Statutory Scheme for Branded Medicines Pricing</em>, is attached.</p><p>There is a wider framework in place to ensure the cost-effectiveness of medicines used in the NHS, most importantly, through National Institute for Health and Care Excellence (NICE) appraisals. This existing framework remains unchanged by the proposals set out in the consultation, with the NHS still required to fund all medicines approved through a NICE technology appraisal. The Department is committed to ensuring access to clinically and cost-effective medicines, and is working with NHS England and the pharmaceutical industry to support improvements in the speed and rate of access to new medicines for NHS patients.</p><p> </p> answering member printed Lord O'Shaughnessy attachment 1 file name Statutory_Scheme_Consultation_Document_corrected.pdf title Proposed changes to the statutory scheme 2 file name 2018_Statutory_Scheme_Impact_Assessment_1.pdf title Statutory Scheme Impact Assessment grouped question UIN HL10416 question first answered 15/10/2018 10:59:00 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

980149

registered interest
date	01/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how the proposed statutory scheme for branded drugs will enhance the position of the UK as a key centre for the life sciences industry.
tabling member printed	Lord Hunt of Kings Heath
uin	HL10418
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>The Government is committed to supporting the United Kingdom life sciences industry as one of the most innovative and internationally competitive sectors of our economy. The statutory scheme is one component in the wider UK medicines landscape, and covers companies who do not sign up to the voluntary scheme (currently the 2014 Pharmaceutical Price Regulation Scheme).</p><p>The impact assessment accompanying the recent <em>Proposed changes to the statutory scheme to control the costs of branded health medicines </em>consultation, concluded that the impact on the UK economy of any foregone research and development investment in response to lower pharmaceutical revenues would be limited, with a net present value impact of -£2.4 million over 2019 to 2021. This is outweighed by positive impacts from reinvesting any savings in the National Health Service leading to net monetised benefits of £1,167 million over the same period. Copies of the consultation document and the impact assessment, <em>2018 Statutory Scheme – Branded Medicines Pricing</em>, are attached.</p><p>The Department has received a number of responses to its recent consultation by members of the public, NHS bodies, industry organisations, as well as individual companies. In considering the responses, the Department will carefully take into account any evidence submitted on the potential impact on the UK life science sector.</p> answering member printed Lord O'Shaughnessy attachment 1 file name Statutory_Scheme_Consultation_Document_corrected.pdf title Statutory_Scheme_Consultation_Document_corrected.p 2 file name 2018_Statutory_Scheme_Impact_Assessment_1.pdf title 2018_Statutory_Scheme_Impact_Assessment_1.pdf question first answered 15/10/2018 13:58:07 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath